CRTAP

Across TCGA pan-cancer cohorts, CRTAP mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CRTAP data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRTAP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRTAP expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and COAD are the cancer types where CRTAP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.242	0.487	<.001	56	view →
CCRCC	OS	Median	III,IV	0.516	0.863	.001	54	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
UCEC	OS	Tertile	All	0.867	1.000	.028	6	view →
GBM	DFS	Quartile	All	0.645	0.831	.014	5	view →
LUAD	DFS	Quartile	III,IV	1.000	0.398	.018	3	view →
HNSC	OS	Median	IV	0.627	0.837	.046	2	view →
LSCC	OS	Tertile	All	0.759	0.917	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CRTAP–PDAC (DFS)

Open the PDAC breakdown →